Effectiveness of Omega-3 Fatty Acids Versus Placebo in Subjects at Ultra-High Risk for Psychosis: The PURPOSE Randomized Clinical Trial.

Background and Hypotheses In the past 2 decades, substantial effort has been put into research on therapeutic options for people at ultra-high risk (UHR) for developing a first episode of psychosis (FEP), focusing on omega-3 polyunsaturated fatty acids (PUFAs) in preventing transition to psychosis....

Descripción completa

Detalles Bibliográficos
Publicado en:Schizophrenia Bulletin Vol. 51; no. 4; pp. 1082 - 1092
Autores principales: Rossum, Inge Winter-van, Slot, Margot I E, Hell, Hendrika H van, Bossong, Matthijs G, Berger, Gregor, Aschauer, Harald, Maat, Arija, Walitza, Susanne, Lavan, Orly, Baeza, Inmaculada, Dolz, Montserrat, Monducci, Elena, Nastro, Paolo Fiori, Kroken, Rune Andreas, Lawrie, Stephen M, Díaz-Caneja, Covadonga Martinez, Renner, Tobias, Schlögelhofer, Monika, Scharinger, Christian, Spalletta, Gianfranco
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: Oxford University Press / USA Jul2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=186630330&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 186630330
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        05867614
        2CZ
      jtl: Schizophrenia Bulletin
      issn: 05867614
      maglogo: N
    pubinfo:
      dt: Jul2025
      vid: 51
      iid: 4
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        186630330
        186630330
        186630330
        10.1093/schbul/sbae186
        186630330
      ppf: 1082
      ppct: 10
      formats:
      tig:
        atl: Effectiveness of Omega-3 Fatty Acids Versus Placebo in Subjects at Ultra-High Risk for Psychosis: The PURPOSE Randomized Clinical Trial.
      aug:
        au:
          Rossum, Inge Winter-van
          Slot, Margot I E
          Hell, Hendrika H van
          Bossong, Matthijs G
          Berger, Gregor
          Aschauer, Harald
          Maat, Arija
          Walitza, Susanne
          Lavan, Orly
          Baeza, Inmaculada
          Dolz, Montserrat
          Monducci, Elena
          Nastro, Paolo Fiori
          Kroken, Rune Andreas
          Lawrie, Stephen M
          Díaz-Caneja, Covadonga Martinez
          Renner, Tobias
          Schlögelhofer, Monika
          Scharinger, Christian
          Spalletta, Gianfranco
        affil: Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands
      sug:
        subj:
          Psychotic Disorders Drug Therapy
          Fatty Acids, omega-3 Therapeutic Use
          Drug Efficacy Evaluation
          Human
          Female
          Male
          Adolescence
          Young Adult
          Randomized Controlled Trials
          Random Assignment
          Double-Blind Studies
          Placebos
          Comparative Studies
          Hospitals, Psychiatric
          Hospitals, Public
          Funding Source
          Descriptive Statistics
          Data Analysis Software
          Psychotic Disorders Prevention and Control
          Europe
          Israel
          Psychotic Disorders Risk Factors
          Adolescent: 13-18 years
          Female
          Male
      ab: Background and Hypotheses In the past 2 decades, substantial effort has been put into research on therapeutic options for people at ultra-high risk (UHR) for developing a first episode of psychosis (FEP), focusing on omega-3 polyunsaturated fatty acids (PUFAs) in preventing transition to psychosis. Despite an initial positive finding, subsequent studies failed to find a beneficial effect. The current study aimed to further investigate the effect of omega-3 PUFAs in UHR, to determine whether this line of research is worth pursuing. Study Design A double-blind, randomized, placebo-controlled study testing the efficacy of 6-month treatment with omega-3 PUFAs in 135 subjects at UHR for FEP, aged 13 to 20 years on the prevention of a transition to psychosis, followed up for 18 months post-treatment. The trial was conducted at 16 general hospitals and psychiatric specialty centers located in 8 European countries and Israel. Study Results There was no beneficial effect of treatment with omega-3 PUFAs compared to placebo; the rate of transition over 2 years did not differ between treatment arms nor was there a difference in change in symptom severity after 6-month treatment. Dropout rates and serious adverse events were similar across the groups. Conclusions This is the third study that fails to replicate the original finding on the protective effect of omega-3 PUFAs in UHR subjects for transition to psychosis. The accumulating evidence therefore suggests that omega-3 PUFAs do not reduce transition rates to psychosis in those at increased risk at 2 years follow-up. Clinical Trials This trial is registered with ClinicalTrials.gov (NCT02597439; Study Details | Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe | ClinicalTrials.gov).
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N